Related Experiment Video
Updated: May 10, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
How to escape the cancer attractor: rationale and limitations of multi-target drugs
1Institute for Systems Biology, Seattle WA, USA. sui.huang@systemsbiology.org
Abstract:
The increasingly evident limitations of target-selective cancer therapy has stimulated a flurry of ideas for overcoming the development of resistance and recurrence - the near universal reason for therapy failure from which target-selective drugs are not exempt. A widely proposed approach to conquer therapy resistance is to depart from the myopic focus on individual causal pathways and instead target multiple nodes in the cancer cell's gene regulatory network. However, most ideas rely on a simplistic conceptualization of networks: utilizing solely their topology and treating it as a display of causal interactions, while ignoring the integrated dynamics in state space. Here, we review the more encompassing formal framework of global network dynamics in which cancer cells, like normal cell types, are high-dimensional attractor states. Then therapy is represented by the network perturbation that will promote the exit from such cancer attractors and reentering a normal attractor. We show in this qualitative and accessible discussion how the idea of a quasi-potential landscape and the theory of least-action-path offer a new formal understanding for computing the set of network nodes (molecular targets) that need to be targeted in concert in order to exit the cancer attractor. But targeting cancer cells based on the network configuration of an "average" cancer cell, however precise, may not suffice to eradicate all tumor cells because of the dynamic non-genetic heterogeneity of cancer cell populations that makes them moving targets and drives the replenishment of the cancer attractor with surviving, non-responsive cells from neighboring abnormal attractors.
Insights
Targeting cancer cells requires a dynamic approach beyond single pathways. Understanding global network dynamics and quasi-potential landscapes can guide therapies to overcome resistance and recurrence.
Area of Science:
- Systems Biology
- Cancer Research
- Computational Biology
Background:
- Target-selective cancer therapies face limitations due to resistance and recurrence.
- Current strategies often focus narrowly on individual causal pathways, neglecting network complexity.
Purpose of the Study:
- To review a formal framework of global network dynamics for cancer therapy.
- To explore how quasi-potential landscapes and least-action-path theory can guide multi-target drug development.
Main Methods:
- Conceptual review of network dynamics as attractor states in gene regulatory networks.
- Application of quasi-potential landscape and least-action-path theory to identify therapeutic targets.
- Discussion of dynamic non-genetic heterogeneity in cancer cell populations.
Main Results:
- Cancer cells can be conceptualized as high-dimensional attractor states within gene regulatory networks.
- Therapy can be viewed as a perturbation to exit cancer attractors and re-enter normal attractors.
- Identifying multiple network nodes for concerted targeting is crucial for effective therapy.
Conclusions:
- Global network dynamics provide a more encompassing framework for understanding and treating cancer.
- Dynamic heterogeneity necessitates adaptive therapeutic strategies beyond targeting an 'average' cancer cell.
- Future cancer therapies should integrate network dynamics and heterogeneity to overcome resistance.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
